Rosen Law Firm Files Class Action Lawsuit Against ADMA Biologics

The complaint alleges that ADMA Biologics misled the market throughout the specified period by failing to disclose significant issues, including undisclosed related-party transactions and the use of channel stuffing to artificially inflate revenue figures. According to the filing, these practices resulted in materially false statements regarding the company’s business operations and financial health. Investors who suffered losses when these details were revealed may be entitled to compensation without incurring out-of-pocket legal fees, as the firm operates on a contingency fee basis.

Those interested in serving as a lead plaintiff must file a motion with the court no later than August 10, 2026. While the lawsuit is currently active, no class has been formally certified. Until certification occurs, investors are not represented by counsel unless they choose to retain an attorney or join the existing action. Shareholders retain the right to remain absent class members or select their own legal representation. For further information, investors can contact Phillip Kim at the Rosen Law Firm.